Open AccessSteroid use and misuse: a key performance indicator in the management of IBD
Author(s) -
Jonathan Blackwell,
Christian P. Selinger,
Tim Raine,
Gareth Parkes,
Melissa Smith,
Richard Pollok
Publication year - 2020
Publication title -
frontline gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.919
H-Index - 13
eISSN - 2041-4145
pISSN - 2041-4137
DOI - 10.1136/flgastro-2019-101288
Subject(s) - medicine , intensive care medicine , inflammatory bowel disease , steroid use , adverse effect , corticosteroid , dependency (uml) , disease , key (lock) , risk analysis (engineering) , surgery , computer security , computer science , software engineering
Corticosteroids remain an important tool for inducing remission in inflammatory bowel disease (IBD) but they have no role in maintenance of remission. The significant adverse side effect profile of these drugs means their use should be avoided where possible or measures taken to reduce their risk. Despite an expanding array of alternative therapies, corticosteroid dependency and excess remain common. Appropriate steroid use is now regarded a key performance indicator in the management of IBD. This article aims to outline indications for corticosteroid use in IBD, their risks and strategies to reduce their use and misuse.